Lymphoma is a cancer that begins in the lymphatic system, a key part of the body’s immune system. It develops when lymphocytes (a type of white blood cell) grow and multiply uncontrollably. There are two main types of lymphoma: Hodgkin lymphoma and non-Hodgkin lymphoma, each with different subtypes and treatment approaches.
Recent advancements in treatment, particularly in cellular therapies, have transformed outcomes for many patients. In some cases, treatments that were once only palliative can now lead to long-term remission or even a cure.
For more resources, visit marybird.org/resources.
However, early detection is key to improving treatment outcomes. If you have presistent symptoms such as,
talk to your doctor to see if a lymphoma screening is right for you.
While lymphoma can affect people of any age, certain factors can increase your risk:
MOST COMMON WARNING SIGN:
OTHER SYMPTOMS INCLUDE:
Mary Bird Perkins Cancer Center offers innovative treatments for lymphoma through our Myeloma, Lymphoma and Cellular Therapy Program, led by Andrew Dalovisio, M.D.
One of the most promising advancements is Bispecific T-cell Engager (BiTE) therapy. This is a type of infusion that works like a matchmaker between the immune system and cancer cells. It helps the body’s immune cells find and destroy the cancer. Because BiTE therapy can be kept in the oncology pharmacy, it’s ready to use quickly, which is especially helpful for patients who need treatment right away.
We also offer Chimeric Antigen Receptor T-cell (CART) therapy. with CART, a patient’s own immune cells (T-lymphocytes) are collected in a simple, minimally invasive procedure. In the lab, these cells are “trained” to recognize and attack the cancer. Once infused back into the patient, they travel throughout the body, targeting cancer cells for destruction. In some cases, this can be a “one and done” treatment, meaning no ongoing therapy is needed after the infusion unless the patient relapses.
Mary Bird Perkins delivers these therapies in an outpatient setting, allowing patients to rest at home surrounded by loved ones instead of staying in the hospital.
Gamma Knife Icon (GKI) is an innovative, noninvasive radiosurgery technology used for treating metastatic breast cancer when tumors have spread to the brain. The first of its kind in the Gulf South, GKI treats only the parts of the brain that need it, sparing healthy tissue and enhancing the quality of life. There are no incisions with this treatment and, in most cases, little to no side effects. To learn more about the Gamma Knife Icon, click here.
Mary Bird Perkins provides genetic counseling and cancer testing services for people who have an increased risk for hereditary cancer. Based on your risk assessment, we can assist you in making informed medical decisions.
People with family history of breast cancer should consult primary care physician for a risk assessment and referral into the program.
Click here to learn more.
Clinical trials are research studies that involve human beings in order to test new ways to prevent, detect, diagnose or treat diseases. A drug must be part of a clinical trial before the FDA will approve it to be put on the market. Oncology clinical trials are conducted in order to test new drugs or a new combination of drug treatments, new surgery and radiation therapies and new medical devices.
Every cancer center patient is evaluated for participation in a clinical trial. Those who meet the criteria to participate in clinical research receive a standard of care treatment, but with the added benefit of a trial that may enhance their outcomes.
If interested in volunteering to participate in a clinical research trial, or if you have concerns about the conduct of clinical research, please contact the Clinical Research office at (225) 215-1353, or by email at clinicalresearch@marybird.com.
